Next Article in Journal
An Emerging Human Parechovirus Type 5 Causing Sepsis-Like Illness in Infants in Australia
Previous Article in Journal
Differential Pathogenicity of SHIV KB9 and 89.6 Env Correlates with Bystander Apoptosis Induction in CD4+ T cells
Previous Article in Special Issue
Prevalence and Correlates of Pre-Treatment HIV Drug Resistance among HIV-Infected Children in Ethiopia
Open AccessReview

Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses

1
Department of Basic and Clinical Sciences, Albany College of Pharmacy and Health Sciences, Albany, NY 12208, USA
2
Department of Immunology and Microbial Disease, Albany Medical College, Albany, NY 12208-3479, USA
*
Author to whom correspondence should be addressed.
Viruses 2019, 11(10), 912; https://doi.org/10.3390/v11100912
Received: 7 August 2019 / Revised: 27 September 2019 / Accepted: 28 September 2019 / Published: 1 October 2019
(This article belongs to the Special Issue Antiviral Agents)
Several notable human diseases are caused by enveloped RNA viruses: Influenza, AIDS, hepatitis C, dengue hemorrhagic fever, microcephaly, and Guillain–Barré Syndrome. Being enveloped, the life cycle of this group of viruses is critically dependent on host lipid biosynthesis. Viral binding and entry involve interactions between viral envelope glycoproteins and cellular receptors localized to lipid-rich regions of the plasma membrane. Subsequent infection by these viruses leads to reorganization of cellular membranes and lipid metabolism to support the production of new viral particles. Recent work has focused on defining the involvement of specific lipid classes in the entry, genome replication assembly, and viral particle formation of these viruses in hopes of identifying potential therapeutic targets for the treatment or prevention of disease. In this review, we will highlight the role of host sphingolipids in the lifecycle of several medically important enveloped RNA viruses. View Full-Text
Keywords: sphingolipids; glycosphingolipids; viruses; lipid biosynthesis; antiviral sphingolipids; glycosphingolipids; viruses; lipid biosynthesis; antiviral
Show Figures

Figure 1

MDPI and ACS Style

Yager, E.J.; Konan, K.V. Sphingolipids as Potential Therapeutic Targets against Enveloped Human RNA Viruses. Viruses 2019, 11, 912.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop